SCHEMBL21922221

SCHEMBL21922221

COc1cc(-c2nc3occn3c2-c2ccnc(NCCN3CCCNS3(=O)=O)n2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 18/20 0.59
RAF1 P04049 14/20 0.59
EGFR P00533 2/20 0.56
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1A1 P48729 1/20 0.42
CLK2 P49760 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
CSNK1G2 P78368 1/20 0.42
TAOK1 Q7L7X3 1/20 0.42
MINK1 Q8N4C8 1/20 0.42
AURKB Q96GD4 1/20 0.42
PRKD2 Q9BZL6 1/20 0.42
HIPK2 Q9H2X6 1/20 0.42
CSNK1G1 Q9HCP0 1/20 0.42
PIM2 Q9P1W9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21922394 0.96 BRAF (0.58) BRAFRAF1EGFRPRKD3MAP4K4
SCHEMBL21922366 0.92 BRAF (0.60) BRAFRAF1EGFR
SCHEMBL21922222 0.90 BRAF (0.60) BRAFRAF1EGFRMAPK8
SCHEMBL21922229 0.90 BRAF (0.65) BRAFRAF1EGFRMAPK8
SCHEMBL21923129 0.88 BRAF (0.68) BRAFRAF1EGFRMAPK8
SCHEMBL21923130 0.88 BRAF (0.71) BRAFRAF1EGFRMAPK8
SCHEMBL20969762 0.88 BRAF (0.77) BRAFRAF1EGFRMAPK8
SCHEMBL21922391 0.88 BRAF (0.61) BRAFRAF1EGFR
SCHEMBL21922396 0.87 BRAF (0.78) BRAFRAF1EGFRMAPK8
SCHEMBL21922364 0.87 BRAF (0.72) BRAFRAF1EGFRMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-05-17 US disclosed
EP-3845539-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Korea Institute of Science and Technology (KR) 2021-07-07 EP disclosed
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME TPMT, MYD88, IDO1 BRAF 159/4885RAF1 978/4885EGFR 2278/4885
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same TPMT, MYD88, IDO1 BRAF 159/4885RAF1 978/4885EGFR 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.